Systematic design of a targeted organometallic antitumor drug in pre-clinical development

Organometallic ruthenium compds. that are effective anticancer and antimetastasis agents are currently under intensive investigation (see also the article by Peter Sadler in this issue). This article provides a personal account of the way in which we have exploited the different properties of the organoruthenium (and osmium and rhodium) compds. to rival traditional DNA-binding platinum drugs, culminating in the discovery of a non-classical mol. that is in an advanced stage of pre-clin. evaluation.


Published in:
CHIMIA, 61, 11, 698-703
Year:
2007
Other identifiers:
Laboratories:




 Record created 2008-03-09, last modified 2018-06-15


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)